Molecular biologists: mark your calendars for 1991. That’s the year BASE Corp. hopes to open a new, $45 million biotechnology lab and pilot plant in the Boston area. Plans for the lab were announced by the North American subsidiary of West Germany’s BASE Group last month. The R&D lab, which will be the chemical giant’s first effort in biotechnology in the U.S., will ultimately employ about 230 people, including 60 scientists. A majority of the staff will be new hires from the U.S. and will work on developing pharmaceuticals for the treatment of cancer and diseases of the immune system. The new facility is expected to complement BASE’s biotechnology research at its headquarters in Ludwigshafen, West Germany, which has developed biotechnological processes for the production of Vitamin B2, natural flavors, 0-lactic acid, and tumor necrosis factor, a potential cancer treatment. BASE, which has an information, systems branch in Bedfbrd, Mass.,...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?